+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Colorectal Cancer Drugs Market by Drug Class, Distribution Channel, Route Of Administration, Line Of Therapy, Target Molecule, Treatment Setting - Global Forecast 2025-2030- Product Image
Colorectal Cancer Drugs Market by Drug Class, Distribution Channel, Route Of Administration, Line Of Therapy, Target Molecule, Treatment Setting - Global Forecast 2025-2030- Product Image
Sale

Colorectal Cancer Drugs Market by Drug Class, Distribution Channel, Route Of Administration, Line Of Therapy, Target Molecule, Treatment Setting - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4896776
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The colorectal cancer drugs market is rapidly evolving, shaped by significant advancements in tumor biology, innovative therapies, and shifting regulatory and economic environments. Senior decision-makers face a highly dynamic environment characterized by changing competitive dynamics and patient needs. This report provides actionable intelligence for stakeholders seeking to optimize growth opportunities and address critical challenges.

Market Snapshot: Colorectal Cancer Drugs Market

The global colorectal cancer drugs market grew from USD 11.36 billion in 2024 to USD 11.95 billion in 2025. It is expected to continue growing at a CAGR of 5.16%, reaching USD 15.37 billion by 2030. This trajectory reflects rising prevalence rates, innovations in precision medicine, and expanded access to advanced therapies across regions.

Scope & Segmentation

This report systematically breaks down the competitive landscape and emerging trends across the entire value chain. Segmentation and regional analysis offer a comprehensive view of the market’s diversity and complexity.

  • Drug Class: Chemotherapy (fluoropyrimidines, platinum compounds, topoisomerase inhibitors), immunotherapy (adoptive cell therapies, checkpoint inhibitors), monoclonal antibodies (epidermal growth factor receptor inhibitors, vascular endothelial growth factor inhibitors), and small molecule inhibitors (BRAF, MEK, and tyrosine kinase inhibitors).
  • Distribution Channel: Hospital pharmacies, online pharmacies, and retail pharmacies each contribute with unique logistics and patient support requirements.
  • Route of Administration: Intravenous, oral, and subcutaneous options impacting workflows and patient experience.
  • Line of Therapy: First, second, and third lines, enabling tailored treatment strategies based on patient response.
  • Target Molecule: Key targets include epidermal growth factor receptor, programmed cell death protein 1, programmed death ligand 1, and vascular endothelial growth factor.
  • Treatment Setting: Coverage of both inpatient and outpatient environments.
  • Regions: Americas (detailed coverage, including United States with focus states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, leading markets in Western and emerging EMEA), and Asia-Pacific (China, India, Japan, Australia, and other high-growth territories).
  • Companies Profiled: Includes Accord Healthcare Limited by Intas Pharmaceuticals Ltd., Amgen Inc., Amneal Pharmaceuticals, Apotex Inc., Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG, Pfizer Inc., and many more leading innovators and emerging competitors.

Key Takeaways for Senior Decision-Makers

  • Scientific advances, especially in immunotherapy and adoption of molecular diagnostics, are driving new approaches to disease management.
  • Precision oncology and biomarker stratification enable more individualized, result-oriented treatments, increasing the need for advanced diagnostics and targeted therapies.
  • Regional market trends vary significantly, with policy frameworks, infrastructure capacity, and access programs influencing adoption in developed and emerging territories.
  • Competitive dynamics grow more intricate as established players, biotech innovators, and consortia expand portfolios through alliances, licensing, and co-development.
  • Patient access to colorectal cancer drugs is influenced by reimbursement patterns, distribution networks, and therapy setting, making market access strategies highly localized.

Tariff Impact: Consequences for Drug Pricing and Supply Chains

Recent United States tariffs on pharmaceutical imports are affecting the supply chain for colorectal cancer therapeutics. Active pharmaceutical ingredient sourcing, manufacturer cost structures, and inventory management are all under pressure, leading to new sourcing strategies and potentially higher logistical expenses. Stakeholders are considering upstream collaborations to mitigate potential disruptions and maintain patient access to essential medications.

Colorectal Cancer Drugs Market: Methodology & Data Sources

The analysis in this report follows a robust framework incorporating systematic literature reviews, expert consultations, and data triangulation from primary and secondary sources. Data includes anonymized prescribing patterns, procurement records, and qualitative interviews with key stakeholders, further validated by panels of experts to ensure methodological rigor and actionable insights.

Why This Report Matters

  • Enables business leaders to navigate translational science breakthroughs, evolving regulations, and complex supply chain risks in the colorectal cancer drugs market.
  • Supports strategic planning by mapping competitive positioning, innovation trends, and pathways for optimized market access across key regions.
  • Delivers a consolidated assessment of technology and partnership models shaping future growth and investment opportunities in colorectal oncology.

Conclusion

This comprehensive research provides senior decision-makers with a data-driven foundation for strategic choices in a fluid and high-stakes sector. The report synthesizes market complexity, innovation, and policy considerations to support sustainable growth and improved patient outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of liquid biopsy biomarker testing to personalize colorectal cancer treatment
5.2. Launch of bispecific antibody therapies for enhanced immunotherapeutic response in CRC
5.3. Regulatory approval landscape for new anti-EGFR agents in metastatic colorectal cancer
5.4. Expansion of oral fluoropyrimidine regimens to improve patient convenience in CRC therapy
5.5. Rising investment in microbiome modulation therapies to target colorectal tumor microenvironment
5.6. Clinical pipeline progression of multi-target tyrosine kinase inhibitors for CRC management
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Colorectal Cancer Drugs Market, by Drug Class
8.1. Introduction
8.2. Chemotherapy
8.2.1. Fluoropyrimidines
8.2.2. Platinum Compounds
8.2.3. Topoisomerase Inhibitors
8.3. Immunotherapy
8.3.1. Adoptive Cell Therapies
8.3.2. Checkpoint Inhibitors
8.4. Monoclonal Antibodies
8.4.1. Epidermal Growth Factor Receptor Inhibitors
8.4.2. Vascular Endothelial Growth Factor Inhibitors
8.5. Small Molecule Inhibitors
8.5.1. BRAF Inhibitors
8.5.2. MEK Inhibitors
8.5.3. Tyrosine Kinase Inhibitors
9. Colorectal Cancer Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Colorectal Cancer Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.4. Subcutaneous
11. Colorectal Cancer Drugs Market, by Line Of Therapy
11.1. Introduction
11.2. First Line
11.3. Second Line
11.4. Third Line
12. Colorectal Cancer Drugs Market, by Target Molecule
12.1. Introduction
12.2. Epidermal Growth Factor Receptor
12.3. Programmed Cell Death Protein 1
12.4. Programmed Death Ligand 1
12.5. Vascular Endothelial Growth Factor
13. Colorectal Cancer Drugs Market, by Treatment Setting
13.1. Introduction
13.2. Inpatient
13.3. Outpatient
14. Americas Colorectal Cancer Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Colorectal Cancer Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Colorectal Cancer Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Accord Healthcare Limited by Intas Pharmaceuticals Ltd.
17.3.2. Amgen Inc.
17.3.3. Amneal Pharmaceuticals, Inc.
17.3.4. Apotex Inc.
17.3.5. Bayer AG
17.3.6. Bristol-Myers Squibb Company
17.3.7. Eisai Co., Ltd.
17.3.8. Eli Lilly and Company
17.3.9. F. Hoffmann-La Roche Ltd
17.3.10. GlaxoSmithKline PLC
17.3.11. HUTCHMED (China) Limited
17.3.12. Lupin Limited
17.3.13. Mallinckrodt Pharmaceuticals
17.3.14. Manus Aktteva Biopharma LLP
17.3.15. Marksans Pharma Ltd.
17.3.16. Merck & Co., Inc.
17.3.17. Mylan N.V. by Viatris Inc.
17.3.18. Novartis AG
17.3.19. Pfizer Inc.
17.3.20. Regeneron Pharmaceuticals, Inc.
17.3.21. Sanofi S.A.
17.3.22. Sumitomo Pharma Co., Ltd.
17.3.23. Taiho Pharmaceutical Co., Ltd. by Otsuka Pharmaceutical Co., Ltd.
17.3.24. Takeda Pharmaceutical Company Limited
17.3.25. VolitionRx Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. COLORECTAL CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2030 (%)
FIGURE 16. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. COLORECTAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. COLORECTAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. COLORECTAL CANCER DRUGS MARKET: RESEARCHAI
FIGURE 28. COLORECTAL CANCER DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 29. COLORECTAL CANCER DRUGS MARKET: RESEARCHCONTACTS
FIGURE 30. COLORECTAL CANCER DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. COLORECTAL CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED DEATH LIGAND 1, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED DEATH LIGAND 1, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 131. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 132. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 133. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 134. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 135. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 136. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 137. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 138. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 139. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 140. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 141. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 144. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 145. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 146. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 147. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 148. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 149. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 150. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 151. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 152. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 153. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 154. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 155. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 156. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 157. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 158. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 159. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 160. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 161. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 162. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 163. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 164. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 165. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 166. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 167. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 168. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 169. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 170. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 242. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 250. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 253. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 254. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 255. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 256. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 257. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 258. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 259. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 260. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 261. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 262. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 263. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 268. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 269. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 270. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 271. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 272. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 273. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 274. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 275. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 276. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 277. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 278. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 279. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 280. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 281. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 282. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 283. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 286. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 287. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 288. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 289. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 290. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 291. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 292. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 293. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 294. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 295. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 296. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 297. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 298. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 299. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 300. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 301. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 302. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 303. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 306. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 307. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 308. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 309. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 310. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 311. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, B

Samples

Loading
LOADING...

Companies Mentioned

  • Accord Healthcare Limited by Intas Pharmaceuticals Ltd.
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • HUTCHMED (China) Limited
  • Lupin Limited
  • Mallinckrodt Pharmaceuticals
  • Manus Aktteva Biopharma LLP
  • Marksans Pharma Ltd.
  • Merck & Co., Inc.
  • Mylan N.V. by Viatris Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Sumitomo Pharma Co., Ltd.
  • Taiho Pharmaceutical Co., Ltd. by Otsuka Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • VolitionRx Limited

Table Information

Report AttributeDetails
No. of Pages199
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.95 Billion
Forecasted Market Value ( USD ) by 2030 $ 15.37 Billion
Compound Annual Growth Rate5.1%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Colorectal Cancer Market Report and Forecast 2025-2034 - Product Image

Colorectal Cancer Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Metastatic Colorectal Cancer Drugs - Global Strategic Business Report - Product Image

Metastatic Colorectal Cancer Drugs - Global Strategic Business Report

  • Report
  • 279 Pages
  • Global
From
Metastatic Colorectal Cancer - Pipeline Insight, 2025 - Product Image

Metastatic Colorectal Cancer - Pipeline Insight, 2025

  • Drug Pipelines
  • 280 Pages
  • Global
From
Colorectal Cancer - Pipeline Insight, 2025 - Product Image

Colorectal Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • 550 Pages
  • Global
From
Metastatic Colorectal Cancer Market: Focus on Drug Class, and Region - Analysis and Forecast, 2025-2035 - Product Image

Metastatic Colorectal Cancer Market: Focus on Drug Class, and Region - Analysis and Forecast, 2025-2035

  • Report
  • 100 Pages
  • Global
From

About the Colorectal Cancer Drug Market

The Colorectal Cancer Drug market is composed of drugs used to treat colon cancer. These drugs are used to reduce the size of tumors, reduce the spread of cancer cells, and reduce the risk of recurrence. Commonly used drugs include chemotherapy, targeted therapy, immunotherapy, and hormone therapy. Chemotherapy is the most common treatment for colon cancer, and is used to kill cancer cells. Targeted therapy is used to target specific molecules in cancer cells, while immunotherapy is used to boost the body’s immune system to fight cancer. Hormone therapy is used to reduce the production of hormones that can cause cancer cells to grow. Companies in the Colorectal Cancer Drug market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.